- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00622466
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with paclitaxel may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving sorafenib together with paclitaxel and to how well it works in treating patients with metastatic breast cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
Primary
- To evaluate the efficacy of sorafenib tosylate and paclitaxel by measuring tumor response, as defined by RECIST criteria, in patients with metastatic, HER2-negative breast cancer.
Secondary
- To evaluate time to disease progression in patients treated with this regimen.
- To evaluate six-month progression-free survival of patients treated with this regimen.
- To evaluate time to treatment failure in patients treated with this regimen.
- To evaluate clinical benefit rate (tumor response and stable disease) at 24 weeks in patients treated with this regimen.
- To evaluate duration of response in patients treated with this regimen.
- To evaluate the tolerability of this regimen in these patients.
- To examine the relationship of gene expression and tissue/serum protein markers, where available, related to response to therapy focusing on growth factor receptor pathways.
OUTLINE: This is a multicenter study.
Patients receive oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 4 weeks.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- University of Texas Southwestern Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically* confirmed breast cancer
Stage IV (metastatic) disease
- Radiographic evidence of metastases NOTE: *Histological confirmation of the actual metastasis is not required.
Measurable disease by RECIST criteria defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (i.e., physical examination, CT scan, MRI, or x-ray) or ≥ 10 mm by spiral CT scan
- No prior radiotherapy unless growth has been documented following radiotherapy
Primary tumor or metastatic tumor HER2-negative, defined as the following:
- Immunohistochemistry of 0 or 1+ OR the equivalent, if an automated quantitative assay is used
- HER2 fluorescent in situ hybridization (FISH) assay negative as defined by a HER2:chromosome 17 centromeric probe ratio < 1.8 (or < 2.2 if immunohistochemistry is less than 3+ or equivalent) OR equivalent values for negative FISH assays that do not normalize to chromosome 17
- Hormone-receptor positive (estrogen receptor-[ER] or progesterone receptor [PgR]-positive) disease or hormone receptor-negative (ER- or PgR-negative) disease
- Tumor block from initial breast cancer primary or a biopsy of a metastatic site must be available for correlative studies
- Brain metastases allowed provided the patient is stable after completion of treatment (i.e., surgery and/or radiotherapy), asymptomatic, and off steroids with 2 consecutive stable brain scans at least 4 weeks after radiotherapy
Exclusion criteria:
- Bone-only or other nonmeasurable-only disease
- Newly diagnosed brain metastases
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-1
- Life expectancy > 6 months
- Menopausal status not specified
- WBC ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Total bilirubin < 1.5 times upper limit of normal (ULN)
- AST and ALT transaminases ≤ 2.5 times ULN (< 5 times ULN if liver involvement)
- Creatinine < 1.5 times ULN OR creatinine clearance > 60 mL/min
- INR < 1.5 OR PT/PTT normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception prior to and during (women and men) and for at least 3 months after (men) study therapy
- Able to swallow and absorb oral medications
Exclusion criteria:
Active or uncontrolled medical illness (e.g., active infection > CTCAE grade 2), including any of the following:
- HIV or chronic hepatitis B or C
- Uncontrolled diabetes
- NYHA class II-IV uncompensated congestive heart failure
- Unstable angina (anginal symptoms at rest)
- New onset angina (i.e., began within the past 3 months)
- Coronary artery disease
- Myocardial infarction within the past 6 months
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- Evidence of bleeding diathesis or coagulopathy
- Pulmonary hemorrhage/bleeding event > CTCAE grade 2 within 4 weeks of first dose of study drug
- Any other hemorrhage/bleeding event > CTCAE grade 3 within 4 weeks of first study drug
- Thrombotic or embolic events (i.e., cerebrovascular accident), including transient ischemic attacks within the past 6 months
- Hypertension that cannot be controlled with medication to ≤ 150/90 mm Hg
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib tosylate
- Prior invasive cancer other than breast cancer except nonmelanoma skin cancer
- Chronic nonhealing wound or ulcer
PRIOR CONCURRENT THERAPY:
- No more than 1 prior chemotherapy regimen for metastatic breast cancer (MBC)
At least 3 weeks since prior hormonal therapy for MBC or adjuvant or neoadjuvant chemotherapy
- More than 1 year since adjuvant paclitaxel
- At least 4 weeks since major thoracic, abdominal, or pelvic surgery and recovered
- At least 3 weeks since prior and no concurrent investigational drugs
- Concurrent bisphosphonates allowed
- Concurrent anticoagulation agents (i.e., warfarin or heparin) allowed
- No anticipated need for or concurrent radiotherapy
- No concurrent Hypericum perforatum (St. John wort) or rifampin (rifampicin)
- No other concurrent anti-neoplastic drugs
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Sorfenib + Paclitaxel
Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
|
The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
Outros nomes:
Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Time to Tumor Progression
Prazo: Time from first treatment to disease progression or death (up to 36 months)
|
Progression-free survival was defined as the time of treatment to the earliest date of documentation of disease progression or death due to any cause.
In the case of a participant started treatment.
Tenth month of progression-free rate of sorafenib and paclitaxel will be compared agains the null progression free rate of 32% using normal approximation test.
|
Time from first treatment to disease progression or death (up to 36 months)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Tumor Response Rate
Prazo: Up to 36 months
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT and MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.
The confirmed response rate was estimated by the number of confirmed responses divided by the total number of participants randomized.
|
Up to 36 months
|
Six-month Progression-free Survival
Prazo: 6 months
|
The proportion of patients with progression-free survival at 6 months.
Progression-free is measured from Day-1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Sole Tumors (RECIST) v1.1, or death on study.
Progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new leasions.
|
6 months
|
Time to Treatment Failure
Prazo: Up to 36 months
|
Number of patients experiencing treatment failure.
|
Up to 36 months
|
Clinical Benefit Rate (Tumor Response and Stable Disease) at 24 Weeks
Prazo: 24 weeks
|
Number of patients with either complete response (CR) or partial response (PR) as defined in Response Evaluation Criteria in Solid Tumors (for patients with measurable disease).
Complete Response: Disappearance of all target lesions, disappearance of all non-target lesions for at least 4 weeks.
Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameters.
|
24 weeks
|
Duration of Response
Prazo: Up to 36 months
|
Number weeks until disease progression measured from Day-1 of study drug administration to disease progression.
|
Up to 36 months
|
Tolerability of Sorafenib/Paclitaxel Regimen
Prazo: Up to 36 months
|
Number of patients without experiencing treatment-related adverse events.
|
Up to 36 months
|
Determine the Relationship of Gene Expression and Tissue/Serum Protein Markers, Where Available, Related to Response to Therapy Focusing on Growth Factor Receptor Pathways.
Prazo: Up to 36 months
|
Median values taken for all assays at baseline and relationship to response vs. no response will be made to identify predictive markers using methods to detect differential expression between two groups samples, including variants of the two-sample t-test, analysis of variance, F-test, and the Wilcoxon rank-sum test.
|
Up to 36 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Barbara B. Haley, MD, Simmons Cancer Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças de pele
- Neoplasias
- Neoplasias por local
- Doenças da mama
- Neoplasias da Mama
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Moduladores de Tubulina
- Agentes Antimitóticos
- Moduladores de Mitose
- Agentes Antineoplásicos Fitogênicos
- Inibidores de proteína quinase
- Paclitaxel
- Sorafenibe
Outros números de identificação do estudo
- STU 082010-161
- ONYX-SCCC-112007-035
- CDR0000587470 (Identificador de registro: PDQ (Physician Data Query))
- NCI-2011-02791 (Identificador de registro: CTRP (Clinical Trials Reporting System))
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de mama
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em paclitaxel
-
Hutchison Medipharma LimitedSun Yat-sen UniversityAtivo, não recrutandoCâncer Gástrico AvançadoChina
-
Shengjing HospitalRecrutamento
-
Anne NoonanNational Cancer Institute (NCI)RecrutamentoCâncer de pâncreas estágio IV AJCC v8 | Adenocarcinoma Pancreático MetastáticoEstados Unidos
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationConcluídoCarcinoma Pulmonar de Células Não Pequenas Recorrente | Câncer de pulmão de células não pequenas em estágio IVEstados Unidos
-
CTI BioPharmaRescindidoNSCLCEstados Unidos, Canadá, Bulgária, Romênia, Federação Russa, Ucrânia, México, Argentina, Hungria, Polônia, Reino Unido
-
CTI BioPharmaRescindido
-
City of Hope Medical CenterNational Cancer Institute (NCI)Ativo, não recrutandoCarcinoma de mama recorrente | Câncer de Mama Estágio IV AJCC v6 e v7 | Câncer de Mama Estágio III AJCC v7 | Câncer de Mama Estágio IIIA AJCC v7 | Câncer de Mama Estágio IIIB AJCC v7 | Câncer de Mama Estágio IIIC AJCC v7 | Carcinoma de Mama Metastático | Carcinoma de Mama Localmente AvançadoEstados Unidos
-
Novartis PharmaceuticalsConcluídoTumores Sólidos Metastáticos ou Localmente AvançadosHolanda, Espanha, Alemanha, Suíça, Bélgica
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Ativo, não recrutandoCâncer de Mama Anatômico Estágio I AJCC v8 | Câncer de mama em estágio anatômico IA AJCC v8 | Câncer de Mama Estágio Anatômico IB AJCC v8 | Câncer de Mama Anatômico Estágio II AJCC v8 | Câncer de mama estágio anatômico IIA AJCC v8 | Câncer de mama estágio anatômico IIB AJCC v8 | Câncer de Mama Anatômico... e outras condiçõesEstados Unidos
-
Mayo ClinicNational Cancer Institute (NCI)RetiradoCarcinoma Urotelial de Bexiga Recorrente | Carcinoma Urotelial de Bexiga Estágio IVEstados Unidos